Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Minerva Neurosciences stock | $2.66

Own Minerva Neurosciences stock in just a few minutes.

Fact checked

Minerva Neurosciences, Inc is a biotechnology business based in the US. Minerva Neurosciences shares (NERV) are listed on the NASDAQ and all prices are listed in US Dollars. Minerva Neurosciences employs 13 staff and has a trailing 12-month revenue of around USD$41.2 million.

How to buy shares in Minerva Neurosciences

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Minerva Neurosciences. Find the stock by name or ticker symbol: NERV. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Minerva Neurosciences reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.66, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Minerva Neurosciences, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Minerva Neurosciences. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Minerva Neurosciences share price

Use our graph to track the performance of NERV stocks over time.

Minerva Neurosciences shares at a glance

Information last updated 2020-12-04.
Latest market closeUSD$2.66
52-week rangeUSD$2.51 - USD$15.215
50-day moving average USD$3.3989
200-day moving average USD$4.0281
Wall St. target priceUSD$6.9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.375

Buy Minerva Neurosciences shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Minerva Neurosciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Minerva Neurosciences price performance over time

Historical closes compared with the close of $2.66 from 2020-12-09

1 week (2021-01-13) N/A
1 month (2020-12-24) 8.13%
3 months (2020-10-20) N/A
6 months (2020-07-20) N/A
1 year (2020-01-20) N/A
2 years (2019-01-20) N/A
3 years (2018-01-20) N/A
5 years (2016-01-20) N/A

Minerva Neurosciences financials

Revenue TTM USD$41.2 million
Gross profit TTM USD$0
Return on assets TTM -3%
Return on equity TTM -36.38%
Profit margin -50.16%
Book value $1.36
Market capitalisation USD$110.5 million

TTM: trailing 12 months

Shorting Minerva Neurosciences shares

There are currently 2.5 million Minerva Neurosciences shares held short by investors – that's known as Minerva Neurosciences's "short interest". This figure is 14% down from 2.9 million last month.

There are a few different ways that this level of interest in shorting Minerva Neurosciences shares can be evaluated.

Minerva Neurosciences's "short interest ratio" (SIR)

Minerva Neurosciences's "short interest ratio" (SIR) is the quantity of Minerva Neurosciences shares currently shorted divided by the average quantity of Minerva Neurosciences shares traded daily (recently around 373807.58928571). Minerva Neurosciences's SIR currently stands at 6.72. In other words for every 100,000 Minerva Neurosciences shares traded daily on the market, roughly 6720 shares are currently held short.

However Minerva Neurosciences's short interest can also be evaluated against the total number of Minerva Neurosciences shares, or, against the total number of tradable Minerva Neurosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Minerva Neurosciences's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Minerva Neurosciences shares in existence, roughly 60 shares are currently held short) or 0.0832% of the tradable shares (for every 100,000 tradable Minerva Neurosciences shares, roughly 83 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Minerva Neurosciences.

Find out more about how you can short Minerva Neurosciences stock.

Minerva Neurosciences share dividends

We're not expecting Minerva Neurosciences to pay a dividend over the next 12 months.

Minerva Neurosciences share price volatility

Over the last 12 months, Minerva Neurosciences's shares have ranged in value from as little as $2.51 up to $15.215. A popular way to gauge a stock's volatility is its "beta".

NERV.US volatility(beta: 1.53)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Minerva Neurosciences's is 1.527. This would suggest that Minerva Neurosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Minerva Neurosciences overview

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of schizophrenia. The company is also developing seltorexant that has completed Phase IIb clinical trial for treating insomnia and major depressive disorders; and MIN-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the roluperidone worldwide, excluding Asia; and co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of seltorexant. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site